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Background. The cost of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) prompted many payers to restrict treat-
ment to patients who met non–evidence-based criteria. These restrictions have implications for survival of people with HCV, espe-
cially for people with human immunodeficiency virus (HIV)/HCV coinfection who are at high risk for liver disease progression. The 
goal of this work was to estimate the effects of DAA access policies on 10-year all-cause mortality among people with HIV.
Methods. The study population included 3056 adults with HIV in the Women’s Interagency HIV Study and Multicenter AIDS 
Cohort Study from 1 October 1994 through 30 September 2015. We used the parametric g-formula to estimate 10-year all-cause 
mortality under DAA access policies that included treating (i) all people with HCV; (ii) only people with suppressed HIV; (iii) only 
people with severe fibrosis; and (iv) only people with HIV suppression and severe fibrosis.
Results. The 10-year risk difference of treating all coinfected persons with DAAs compared with no treatment was –3.7% (95% 
confidence interval [CI], –9.1% to .6%). Treating only those with suppressed HIV and severe fibrosis yielded a risk difference of 
–1.1% (95% CI, –2.8% to .6%), with 51% (95% CI, 38%–59%) of coinfected persons receiving DAAs. Treating a random selection of
51% of coinfected persons at baseline decreased the risk by 1.9% (95% CI, –4.7% to .3%).
Conclusions. Restrictive DAA access policies may decrease survival compared to treating similar proportions of people with 
HIV/HCV coinfection with DAAs at random. These findings suggest that lives could be saved by thoughtfully revising access policies.
Keywords. hepatitis C virus; human immunodeficiency virus; antiretroviral therapy; direct-acting antivirals; population inter-
vention effects.
Given the many comorbidities associated with human immu-
nodeficiency virus (HIV), understanding the impact of inter-
ventions for these conditions is essential for allocating patient, 
clinician, and public resources. Liver-related complications are 
a major cause of death among people with HIV (PWH), largely 
due to hepatitis C virus (HCV) coinfection [1, 2]. Fortunately, 
the advent of direct-acting antiviral (DAA) treatments has dra-
matically changed the outlook for people with HIV/HCV coin-
fection; sustained HCV virologic response (SVR) is achievable 
in >90% of PWH [3].
To limit expenditures, payers have restricted DAA treat-
ment to those who meet certain criteria. As of October 2018, 15 
Medicaid programs restricted DAA treatment based on liver fi-
brosis, with 7 limiting access to those beneficiaries at or nearing 
cirrhosis [4]. Achievement of HIV benchmarks for persons 
with HIV/HCV coinfection, such as suppressing HIV viremia, 
has been used as a restriction for DAA treatment in 5 states plus 
Washington, District of Columbia [5]. These restrictions per-
sist and treatment denials remain common [6] despite guide-
lines recommending DAA treatment for nearly all patients with 
HCV [7]. Because these policies are evolving [8], evidence is 
needed to properly evaluate how such restrictions impact mor-
tality—especially for people with HIV/HCV coinfection who 
are at elevated risk for liver disease progression [9].
Our goal was to evaluate the impact of restrictions for DAA 
use on 10-year, all-cause mortality among PWH at 2 levels. 
First, we estimated the effects of various DAA treatment poli-
cies on mortality among HIV/HCV-coinfected persons to de-
termine how much mortality could be averted by expanding 
access to DAAs. Second, we estimated the population-level 
impact of these criteria on mortality among the entire popula-
tion of PWH. These estimates consider the prevalence of HCV 
among PWH, and thus facilitate comparisons of HCV treat-
ment interventions with interventions for other comorbidi-
ties. Together, these results provide an important perspective 




Our data came from ongoing, US-based HIV cohorts of men 
who have sex with men (Multicenter AIDS Cohort Study 
[MACS]) [10] and women (Women’s Interagency HIV Study 
[WIHS]) [11, 12]. MACS began enrollment in 1984, with ad-
ditional recruitment in 1987, 2001, and 2010 in 4 cities. WIHS 
opened in 1994 in 6 cities and added additional participants 
in 2001, 2011, and 2013; it now represents 10 urban and sub-
urban locations. In both cohorts, participants attend semian-
nual visits for laboratory testing, clinical examinations, and 
interviews. Information collected at these visits includes med-
ication use, sociodemographic and behavioral characteristics, 
CD4 cell count and HIV RNA, and HCV antibody and RNA. 
Additionally, scores assessing liver fibrosis (Fibrosis-4 Index 
for Liver Fibrosis [FIB-4] [13] and aspartate aminotransferase–
to-platelet ratio index [APRI] [14]) are calculated for all partici-
pants. The WIHS and MACS were approved by the institutional 
review boards of participating institutions, and all participants 
provided informed consent.
Eligibility for this analysis required documentation of HIV 
infection at cohort entry or HIV seroconversion during fol-
low-up (with inclusion beginning at the visit corresponding to 
HIV diagnosis). Only visits after the start of WIHS recruitment 
(1 October 1994) were included. All participants were required 
to be antiretroviral therapy (ART) naive (defined below) and 
free of an AIDS diagnosis at their first eligible visit. Follow-up 
lasted until the first of: loss to follow-up (the date of a partic-
ipant’s second consecutive missed study visit), death, 10 years 
after the first eligible visit, or 30 September 2015.
Definitions
The presence of antibody (Ab) against HCV was tested at 
baseline in both studies by enzyme immunoassay. Reactive 
specimens underwent HCV RNA testing by nucleic acid am-
plification; those with detectable HCV RNA were considered 
to have active, chronic HCV infection. Participants who lacked 
HCV RNA tests but had reactive HCV Ab were considered to 
have missing HCV data.
The definition of ART was guided by the November 2014 
US Department of Health and Human Services guidelines 
[15]. Any 3-drug regimen including at least 1 protease in-
hibitor, entry inhibitor, integrase inhibitor, or nonnucleoside 
reverse transcriptase inhibitor was considered ART. Once a 
participant initiated ART, they were assumed to remain on it 
for the remainder of follow-up. ART initiated after 1 October 
2001 (the first visit following the approval of tenofovir, a com-
ponent of many current ART regimens [16]) was considered 
“modern ART.”
Date and cause of death were identified either directly through 
periodic searches of the National Death Index or through copies 
of death certificates obtained by study investigators.
Confounders
Confounders for the ART-on-mortality and HCV-on-
mortality relationships were chosen using a causal diagram 
[17] (Supplementary Figure 1). Baseline confounders were age,
sex, race/ethnicity, CD4 count, HIV RNA, injection drug use
(IDU), heavy alcohol use (defined as >7 drinks per week for
women and >14 drinks per week for men [18]), smoking, obe-
sity, and liver fibrosis. Time-varying confounders for the ART-
on-mortality relationship included CD4 count, HIV RNA, IDU, 
heavy alcohol use, smoking, obesity, and liver fibrosis. Fibrosis
was categorized into 3 levels: FIB-4 ≥3.25 or APRI ≥1 was clas-
sified as severe fibrosis/cirrhosis, whereas FIB-4  <1.45 and
APRI  <0.7 (together) was classified as no significant fibrosis.
Other combinations were considered moderate fibrosis. The
APRI cutoffs were guided by a meta-analysis [14] that suggested 
these perform better than commonly used cutoffs of 2 and 0.5,
respectively. Details on variable measurement and operational-
ization are shown in the Supplementary Appendix.
Statistical Analysis
We compared the risk of 10-year, all-cause mortality among 
HIV/HCV-coinfected persons and their risk under DAA access 
policies including treating (i) all HIV/HCV-coinfected persons; 
(ii) HIV/HCV-coinfected persons who meet certain precondi-
tions (HIV suppression, severe fibrosis or cirrhosis, or both);
and (iii) treating the same proportion of HIV/HCV-coinfected
persons as in (ii) chosen randomly without clinical restric-
tions. Additionally, we estimated the population intervention
analogues of the above effects that compare mortality among
all PWH to mortality had HIV/HCV-coinfected persons been
treated according to each of the criteria [19–21]. Each effect was 
estimated under a hypothetical intervention to have all partic-
ipants initiate modern ART at baseline, including those who
entered the study prior to 2001. Each effect is defined in detail
in the Supplementary Appendix.
Because insufficient person-time has accrued in the DAA 
era to estimate long-term effects, the above effects cannot be 
directly estimated with existing data. Instead, we used data col-
lected prior to the DAA era along with strong assumptions to 
estimate the effects in this study. Specifically, we assumed that 
an HCV-seronegative person has the same risk of mortality as 
a person with HCV after successful treatment of their HCV in-
fection, provided they both have similar degrees of liver fibrosis 
and are of similar age, race and ethnicity, sex, smoking status, 
etc. We conducted a sensitivity analysis restricted to those neg-
ative for hepatitis B virus (HBV) surface antigen at baseline, as 
HBV is known to be associated with liver fibrosis and mortality, 
and thus may lead to a violation of this assumption.
We estimated the mortality risk under each policy using the 
parametric g-computation algorithm (referred to as g-com-
putation) [22]. The g-computation is an extension of direct 
standardization that accommodates time-varying confound-
ers and dynamic treatment regimens [23]. Our implementa-
tion involves conducting multiple microsimulations within 
a single, enlarged cohort, with each microsimulation corre-
sponding to a different treatment policy [24, 25]. The enlarged 
cohort consisted of 50 000 individuals randomly sampled with 
replacement from the eligible MACS/WIHS participants. We 
used pooled regressions to model mortality and the time-vary-
ing confounders in the MACS/WIHS. Using these models, 
we simulated the time-varying confounder histories and sur-
vival curves that would occur in the enlarged cohort under 
each DAA policy, and we compared 10-year mortality for 
each policy. We assumed that DAAs had an average effective-
ness of 96% [26]. Confidence limits were estimated using the 
nonparametric bootstrap percentile method with 1000 repli-
cates [27]. Further details of g-computation are shown in the 
Supplementary Appendix.
We used multiple imputation to handle missing baseline 
data with a multivariate normal imputation model [28]. The 
proportion missing for each variable ranged from 0% to 30% 
(for fibrosis, specifically). Missing time-varying covariates 
were carried forward from the most recent measurement. The 
results remained similar when linear interpolation was used for 
missing time-varying covariates. We incorporated multiple im-
putation into the bootstrap with the “Boot MI” algorithm [29] 
with 20 imputed datasets per replicate. All statistical analyses 




A total of 3056 PWH were included in the study (1777 women, 
1279 men). The prevalence of HCV was 18% (27% among 
women; 7% among men). Follow-up lasted a median of 7.5 years 
(interquartile range, 2–10 years). Those with HIV/HCV coin-
fection were generally older; were more likely to be female; had 
lower CD4 counts; were more likely to use injection drugs, drink 
heavily, or smoke; and had worse fibrosis at baseline (Table 1). 
ART was prescribed to 63% of participants, 32% of whom ini-
tiated a modern ART regimen. The observed and modeled dis-
tributions of key variables were similar (Supplementary Table 1 
and Supplementary Figure 2).
Estimated Effects of DAA Access Criteria
The risk difference (RD) comparing 10-year all-cause mortality 
risk among coinfected persons who were not treated for HCV 
to what would be expected if all were treated with DAAs was 
–3.7% (95% confidence interval [CI], –9.1% to .6%; Table 2).
This corresponds to a 10-year number needed to treat (NNT) of 
27, meaning coinfected individuals would need to receive DAA 
treatment to prevent 1 death over 10 years.
If only those coinfected persons with undetectable HIV RNA 
received DAAs, mortality risk would be reduced by –1.9% (95% 
CI, –5.2% to .5%), for a 10-year NNT of 52 (meaning that this 
policy must be applied to 52 coinfected persons to prevent 1 
death over 10 years [30]). Under this criterion, 90% (95% CI, 
84%–93%) of coinfected persons would be treated with DAAs. 
The effect of treating the same proportion of coinfected persons 
at baseline without regard for HIV viral suppression (that is, 
the effect of randomly choosing 90% of coinfected persons at 
baseline to receive treatment) was an expected mortality risk 
reduction of –3.3% (95% CI, –8.1% to .5%), for a 10-year NNT 
of 30 (Figure 1 and Table 2).
Only providing DAAs to coinfected persons with severe fi-
brosis or cirrhosis would be expected to reduce the risk of 
mortality by –1.6% (95% CI, –4.7% to .8%), and 60% (95% 
CI, 45%–70%) of coinfected persons would receive treatment. 
The corresponding 10-year NNT is 62. If the same proportion 
of coinfected persons were randomly selected for treatment at 
baseline, mortality risk would be reduced by –2.2% (95% CI, 
–5.6% to .3%), for a 10-year NNT of 45 (Figure 1 and Table 2).
Finally, by only treating coinfected persons with severe fi-
brosis or cirrhosis who have undetectable HIV RNA, the risk
of mortality would be expected to decline by –1.1% (95% CI,
–2.8% to .6%), and 51% (95% CI, 38%–59%) of coinfected
persons would be treated. This translated into a 10-year NNT
of 94. By treating the same proportion of coinfected persons
at baseline without these restrictions, mortality would be ex-
pected to decline by –1.9% (95% CI, –4.7% to .3%; Figure 1
and Table 2), and the NNT is 53. The timing of DAA treat-
ments under each set of treatment criteria is presented in
Supplementary Figure 3. Though the magnitude of the effects
estimated after excluding those with HBV at baseline are
somewhat larger than in the main analysis, the overall pat-
tern of the results remains the same (Supplementary Table 2).
The amount of person-time on treatment for each policy is
displayed in Supplementary Table 3.
Estimated Population Intervention Effects of DAA Access Criteria
The RD comparing the 10-year all-cause mortality risk in the 
entire population of PWH to the risk in the entire population 
that would be expected if all coinfected persons received DAAs 
was –0.7% (95% CI, –1.8% to .1%; Table 3).
If only coinfected persons with undetectable HIV RNA re-
ceived DAAs, the mortality risk among all PWH would be ex-
pected to be reduced by –0.4% (95% CI, –1.0% to .1%). In this 
scenario, 90% (the same proportion reported in the previous 
section) of coinfected persons received DAAs. The effect of 
treating the same proportion of coinfected persons randomly 
at baseline was an expected –0.6% (95% CI, –1.6% to .1%) de-
crease in mortality among all PWH (Table 3).
Treating only coinfected persons with severe fibrosis or cir-
rhosis with DAAs would lead to an expected –0.3% (95% CI, 
–.8% to .2%) reduction in mortality among all PWH, and 60% 
of coinfected persons would be treated. Treating the same 
proportion of coinfected persons at baseline without fibrosis 
restrictions would reduce mortality among all PWH by –0.4% 
(95% CI, –1.1% to .1%; Table 3).
Finally, the effect of treating only coinfected persons with 
severe fibrosis or cirrhosis and undetectable HIV RNA was an 
estimated –0.2% (95% CI, –.5% to .1%) reduction in mortality 
risk among all PWH, and 51% of coinfected persons would 
be treated. If the same proportion of coinfected persons was 
treated without these restrictions, the mortality risk among all 
PWH would decrease by –0.4% (95% CI, –.9% to .1%; Table 3).
DISCUSSION
Use of common eligibility criteria for DAA treatment among 
people with HIV/HCV coinfection consistently yields a 
Table 1. Baseline Characteristics of Eligible Participants From the Women’s Interagency Human Immunodeficiency Virus Study and Multicenter AIDS 
Cohort Study, 1994–2015
Characteristic
Women's Interagency HIV Study Multicenter AIDS Cohort Study
HCV+ HCV– HCV+ HCV–
(N = 460) (N = 1231) (N = 83) (N = 1180)
Age, y, median (IQR) 40 (35–44) 34 (29–40) 44 (40–50) 40 (34–45)
Race
White (non-Hispanic) 74 (16.1) 178 (14.5) 35 (42.2) 802 (68.0)
African American 281 (61.1) 710 (57.7) 40 (48.2) 247 (20.9)
 Hispanic 99 (21.5) 293 (23.8) 8 (9.6) 116 (9.8)
 Other 6 (1.3) 49 (4.0) 0 (0.0) 15 (1.3)
 Missing 0 … 1 … 0 … 0 …
CD4 count, cells/μL, median (IQR) 373 (213–575) 410 (262–609) 405 (250–652) 433 (280–605)
 Missing 13 … 36 … 3 … 103 …
Detectable HIV RNAa 428 (95.3) 1137 (94.3) 59 (96.7) 692 (96.2)
 Missing 11 … 25 … 22 … 461 …
IDU
 Never 61 (13.3) 1096 (89.1) 41 (52.6) 1060 (91.9)
 Former 293 (63.7) 106 (8.6) 7 (9.0) 56 (4.9)
 Current 106 (23.0) 28 (2.3) 30 (38.5) 38 (3.3)
 Missing 0 … 1 … 5 … 26 …
Heavy alcohol useb 93 (20.8) 143 (11.9) 9 (11.7) 109 (9.5)
 Missing 12 … 28 … 6 … 29 …
Smoking
 Never 47 (10.3) 502 (40.9) 11 (14.3) 335 (29.0)
 Former 58 (12.7) 215 (17.5) 19 (24.7) 386 (33.4)
 Current 353 (77.1) 510 (41.6) 47 (61.0) 433 (37.5)
 Missing 2 … 4 … 6 … 26 …
Obese 97 (22.6) 382 (31.7) 8 (10.5) 100 (10.2)
 Missing 30 … 25 … 7 … 201 …
HBsAg positive 12 (2.6) 28 (2.3) 5 (6.2) 81 (7.1)
 Missing 2 … 12 … 2 … 42 …
Fibrosis statusc
No significant fibrosis 211 (51.2) 1004 (86.0) 14 (29.8) 358 (81.0)
Moderate fibrosis 112 (27.2) 103 (8.8) 15 (31.9) 59 (13.3)
Severe fibrosis/cirrhosis 89 (21.6) 60 (5.1) 18 (38.3) 25 (5.7)
 Missing 48 … 64 … 36 … 738 …
ART
Initiated before October 2001 212 (46.1) 521 (42.3) 17 (20.5) 513 (43.5)
Initiated after October 2001 33 (7.2) 269 (21.9) 19 (22.9) 268 (22.7)
Data are presented as no. (%) unless otherwise indicated. One hundred two participants had missing HCV status.
Abbreviations: ART, antiretroviral therapy; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile 
range.
aLower limit of detection varied over time and ranged from 500 copies/mL to 20 copies/mL.
bDefined as >7 drinks per week for women and >14 drinks per week for men [18].
cCirrhosis defined as Fibrosis-4 Index for Liver Fibrosis (FIB-4) ≥3.25 or aspartate aminotransferase-to-platelet ratio index (APRI) ≥1; no significant fibrosis defined as FIB-4 <1.45 and 
APRI <0.7; other combinations were classified as noncirrhotic fibrosis.
smaller decline in 10-year all-cause mortality than select-
ing a similar proportion of persons at random at baseline, 
without any eligibility criteria. Treating people at baseline 
would require providing treatments earlier than under the 
criteria we investigated and could therefore entail higher 
upfront costs (Supplementary Figure 3). However, the addi-
tional 10-year mortality benefit of earlier treatment is sub-
stantial. Stated differently, providing treatment to those who 
achieve HIV suppression and progress to severe fibrosis or 
cirrhosis led to treatment of 51% of coinfected persons on 
average. We estimated that the same 10-year mortality ben-
efit would be achieved by treating only 28% of coinfected 
persons at baseline chosen randomly, nearly halving the 
proportion treated.
The worse mortality outcomes conferred by restrictive eligi-
bility criteria are not surprising; these criteria were developed 
based on financial considerations, in contrast to evidence-based 
guidelines that recommend treating nearly all persons with 
HCV [7]. By only treating coinfected individuals who have se-
vere fibrosis or cirrhosis, we may be intervening too late in the 
HCV disease process. At that stage of liver disease, the increased 
risk of adverse outcomes due to fibrosis and cirrhosis may atten-
uate the benefit of DAA treatment.
These findings suggest that setting treatment access poli-
cies with only short-term cost-containment in mind can cause 
patients unnecessary harm, and lives may have been saved if 
careful consideration had been used to set DAA treatment 
policies. These restrictive policies were likely well-intentioned, 
as deferring treatment may have been in anticipation of mar-
ket-driven DAA price reductions that would allow wider ac-
cess in the future. However, such considerations are somewhat 
obviated by the mortality reduction we estimated for treating 
patients at baseline without consideration of clinical factors. 
In addition, SVR has been shown to improve patient-reported 
outcomes [31, 32], so the benefits of improved treatment alloca-
tion are expected to extend beyond improved survival.
Our population intervention effect estimates additionally 
incorporate the proportion of PWH who would be treated. As 
such, these estimates can be compared with similar estimates 
for other conditions in this population and can be used to prop-
erly compare interventions for different comorbidities. Similar 
effects should be estimated for other conditions impacting 
PWH to optimally allocate limited treatment resources.
Because our study mostly predates the DAA era, our esti-
mates rely on the assumption that PWH who are not coinfected 
with HCV had the same mortality that similar people with 
HIV/HCV coinfection would have had with successful DAA 
treatment. While studies have found improved liver function 
and reduced risks of HCV-related complications after suc-
cessful DAA treatment [33, 34], none have compared those who 
achieve SVR to those who never had HCV, and thus the validity 
of this assumption remains an open question. One concern 
with this assumption is that HCV-uninfected individuals with 
fibrosis must have another underlying condition affecting the 
liver. We controlled for several risk factors for fibrosis, such as 
alcohol use, injection drug use, and obesity, but others probably 
remain. While the effects estimated after excluding those with 
HBV (a known cause of fibrosis) displayed a similar pattern as 
those in the main analysis, other violations of our assumptions 
are likely.
Our study is subject to additional limitations. First, we did not 
model incident or recurring HCV infections (and retreatment). 
Multiple recent studies have estimated reinfection rates among 
PWH of approximately 30 per 1000 person-years [35–37]. 
Second, over the course of this study, HIV RNA measurement 
and ART regimens have improved. Of the 10 888 person-visits 
with undetectable HIV RNA, 117 were classified based on tests 
with lower limits of detection >100 copies/mL. We conducted 
Table 2. Effects of Direct-acting Antiviral Treatment Criteria on 10-Year All-cause Mortality Among People With Human Immunodeficiency Virus (HIV) and 
Hepatitis C Virus, Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 1994–2015
Treatment










RD: Treat According to Criteria vs Treat 
Same, % at Randomd
No intervention 0 19.2 (11.0–30.4) Ref … … …
All HCV treated 100 15.4 (9.0–24.2) –3.7 (–9.1 to .6) … … …
Only HIV suppressed treatede 89.6 (84.3–93.0) 17.2 (10.3–26.4) –1.9 (–5.2 to .5) 15.8 (9.3–24.8) –3.3 (–8.1 to .5) 1.4 (–.3 to 3.6)
Only severe fibrosis treatede 59.9 (44.3–69.4) 17.5 (10.5–27.0) –1.6 (–4.7 to .8) 16.9 (9.8–26.7) –2.2 (–5.6 to .3) 0.6 (.0–1.4)
Only HIV suppressed and severe 
fibrosis treatede
51.0 (37.9–59.1) 18.1 (10.7–28.1) –1.1 (–2.8 to .6) 17.2 (10.0–27.2) –1.9 (-4.7 to .3) 0.8 (–.1 to 2.4)
Data in parentheses indicate the 95% confidence interval.
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; RD, risk difference.
aPercentage of all people with HIV/HCV coinfection treated with direct-acting antivirals.
bComparing treating according to criteria to no treatment.
cComparing treating the same percentage of people at random at baseline to no treatment.
dComparing treating according to criteria to treating the same percentage of people at random at baseline.
eIncludes those who meet the criteria at baseline as well as those who progress to meet it during follow-up.
a sensitivity analysis classifying these measurements as detect-
able, and the results were unchanged. Additionally, each effect 
was estimated under a hypothetical intervention to have all 
subjects initiate “modern” ART, including those who entered 
the study prior to 2001, thus reducing treatment heterogeneity 
over the study period. Third, our study sample consisted of 
Table 3. Population Intervention Effects of Direct-acting Antiviral Treatment Criteria on 10-Year All-cause Mortality Among All People With Human Immunodeficiency 
Virus (HIV) (Including Those With and Without Hepatitis C Coinfection), Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 1994–2015
Intervention All HCV Treated, %
Only HIV Suppressed 
Treated, %b
Only Severe Fibrosis 
Treated, %b
Only HIV Suppressed and  
Severe Fibrosis Treated, %b
% Treateda 100 89.6 (84.3–93.0) 59.9 (44.3–69.4) 51.0 (37.9–59.1)
RD: Treat according to criteria vs no treatment –0.7 (–1.8 to .1) –0.4 (–1.0 to .1) –0.3 (–.9 to .2) –0.2 (–.5 to .1)
RD: Treat same % at random vs no treatment … –0.6 (–1.6 to .1) –0.4 (–1.1 to .1) –0.4 (–.9 to .1)
RD: Treat according to criteria vs treat same 
% at random
… 0.3 (–.1 to .7) 0.1 (.0–.3) 0.2 (0–.4)
Data in parentheses indicate the 95% confidence interval.
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; RD, risk difference.
aPercentage of all people with HIV/HCV coinfection treated with direct-acting antivirals.
bIncludes those who meet the criteria at baseline as well as those who progress to meet it during follow-up.
Figure 1. Ten-year risk of all-cause mortality under direct-acting antiviral treatment criteria among people with human immunodeficiency virus (HIV) and hepatitis C virus 
in the Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 1994–2015. A, Treat none at baseline (solid line) vs treat all at baseline (dotted line). B, Treat once 
HIV virally suppressed (solid line) vs treat same percentage of people at random at baseline (dotted line). C, Treat once progressed to severe fibrosis or cirrhosis (solid line) 
vs treat same percentage of people at random at baseline (dotted line). D, Treat once HIV virally suppressed and progressed to severe fibrosis or cirrhosis (solid line) vs treat 
same percentage of people at random at baseline (dotted line). Note that in all 4 panels, a lower curve indicates lower mortality, and thus in panels (B–D), treating people at 
random at baseline is generally superior to treating based on the stated criteria.
cohorts of men who have sex with men and women in roughly 
even proportions, with data dating back to 1994. Our results 
therefore may not generalize to the current population of PWH 
in the United States [38]. Finally, because we explored the out-
come of 10-year, all-cause mortality, it is expected that future 
changes in treatment cost and efficiency, as well as other contex-
tual factors, will occur that may alter the effects of the policies 
under study.
DAA access in the United States is rapidly evolving. Though 
many DAA restrictions requiring patients to meet clinical pre-
conditions are being updated [8], as of October 2018, 30% of 
Medicaid programs still limit treatment to those with some de-
gree of liver fibrosis [4], and treatment denials remain common 
across the country [6]. Until more person-time accumulates 
in the DAA era, estimates that rely on observational data, like 
those we present, are needed to evaluate the effects of treatment 
policies on long-term outcomes most pertinent to HCV, a di-
sease that progresses slowly over decades. As we proceed further 
into the DAA era, studies should directly evaluate the impact of 
HCV treatment policies among people with HIV/HCV coinfec-
tion to optimize the delivery of DAAs in this population.
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